Pharmasset, Inc. Company Profile
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.
303-A College Road East
United States of America
Phone: (609) 613-4100
Fax: (609) 613-4150
ByAustrolib:Merck's (MRK) acquisition of Idenix (IDIX) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have been published on Seeki...
Gilead Sciences Inc. (NASDAQ:GILD) disclosed in an SEC filing that an arbitration panel ruled Roche (SIX:ROG; OTCQX:RHHBY) failed to establish its claims to Gilead's HCV drug Sovaldi sofosbuvir. Roche...
Ebb & Flow OnCore performance After helping to develop blockbuster HCV drug Sovaldi sofosbuvir, a team of ex-Pharmasset Inc. executives now have lined up money and assets in OnCore Biopharma Inc. and ...
Two members of the Senate Finance Committee requested pricing information for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), including an explanation of the difference between th...
Sens. Ron Wyden, D-Ore., and Charles Grassley, R-Iowa, send letter to the drug's maker requesting information about how it set the price, which runs about $84,000 for a standard three-month regimen. T...
HBV play OnCore Biopharma Inc. (Doylestown, Pa.) acquired infectious disease company Enantigen Therapeutics Inc. (Doylestown, Pa.) in an all-cash deal of undisclosed size. OnCore gains two HBV program...
By Pharma Doc: Introduction: Gilead (NASDAQ:GILD) is an innovative biotech company that has continued to provide superior innovation leading to transformational drugs primarily in antivirals (HIV). ...
Gilead will price the first all-oral treatment for the virus, to hit the market in October, above the current $84,000 Sovaldi formulation, which is prescribed and taken with ribav...
Drugs and Medications
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...
More Information about "Pharmasset, Inc." on BioPortfolio
We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.